Neuroendocrine tumors (NETs) are a heterogeneous class of diseases characterized by challenging management. Preclinical evidence shows that the PI3K/AKT/mTOR signaling pathway plays a central role in the pathogenesis and progression of NETs. Everolimus is a direct inhibitor of this pathway. and therefore this molecule appears to be a well-grounded strategy for the treatment of NETs. https://missouriquiltcoes.shop/product-category/missouri-star-publications/